Comparative Analysis of a First and Second-Generation Commercially Available Platelet-Rich Plasma Concentration System

Background: The use of orthobiologics, particularly platelet-rich plasma (PRP), has become increasingly prevalent for the treatment of musculoskeletal pathologies. However, there is limited research comparing the PRP yields from different commercially available systems. In 2024, the second-generation EmCyte PurePRP® TWO GenesisCS 120 mL Concentrating System was released, and the GS120-PurePRP® II 120mL Concentrating System was retired. Methods: This study evaluates the platelet concentrate products from these two PRP systems. A retrospective review of registry data from 20 consecutive patients treated with intra-articular PRP injections for knee osteoarthritis (OA) was conducted. Platelet recovery rate, deliverable platelet dose, and white (WBC) and red blood cell (RBC) counts were analyzed. Results: There were no statistically significant differences in platelet recovery (P = 0.4094) or deliverable platelet dose (P = 0.4104) between the two systems. Conclusion: Platelet recovery rate and dose, WBC and RBC counts were similar between the newly released and legacy systems.